Основные принципы терапии анкилозирующего спондилита (болезни Бехтерева)

The history of treatment of ankylosing spondylitis (AS) and the reasons behind the development of modern approaches to its therapy are briefly described. The main tasks and principles of non-pharmacological and drug therapies for AS are briefly reported. The need for therapeutic physical training is emphasized, since its role in maintaining the functional status in this group of patients has been proved. The lecture casts doubt on effectiveness of physiotherapy and other physical techniques because of the poor evidence base. The lecture emphasizes the disease-modifying role of nonsteroidal anti-inflammatory drugs and requirement to receive them constantly for patients with Bechterew's disease. Meanwhile, the basic anti-inflammatory drugs in patients with this disease are reported to play an auxiliary role and to have no effect on disease progression. The pronounced clinical effectiveness of all tumor necrosis factor α inhibitors is emphasized; certain differences in their therapeutical effect are described. The problems of surgical treatment, which deal with correction of disease complications or undesirable effects, are discussed.

[1]  Sergey Solovyev,et al.  ИЗУЧЕНИЕ РОЛИ ИММУНОГЕННОСТИ ИНФЛИКСИМАБА В ТЕРАПИИ АНКИЛОЗИРУЮЩЕГО СПОНДИЛИТА , 2016, RSP 2016.

[2]  Н. В. Изможерова,et al.  Сравнительная оценка влияния ряда препаратов с психотропным действием на центральную нервную систему экспериментальных животных, на фоне хронической алкогольной интоксикации в хронофармакологическом аспекте , 2016 .

[3]  Елена Николаевна Александрова,et al.  Эффективность адалимумаба при раннем ревматоидном артрите в зависимости от уровня препарата в сыворотке крови и наличия антилекарственных антител , 2014, RSP 2014.

[4]  Junmin Chen,et al.  Sulfasalazine for ankylosing spondylitis. , 2014, The Cochrane database of systematic reviews.

[5]  W. Dhert,et al.  Clinical outcome after traumatic spinal fractures in patients with ankylosing spinal disorders compared with control patients. , 2014, The spine journal : official journal of the North American Spine Society.

[6]  M. Dougados,et al.  Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials , 2013, Annals of the rheumatic diseases.

[7]  M. Dougados,et al.  Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force , 2013, Annals of the rheumatic diseases.

[8]  V. Mazurov,et al.  Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1 , 2013, Annals of the rheumatic diseases.

[9]  A. Deodhar,et al.  The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial , 2013, Annals of the rheumatic diseases.

[10]  J. Braun,et al.  Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial , 2013, Annals of the rheumatic diseases.

[11]  D. Poddubnyy,et al.  Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis – a five-year update , 2013, Expert opinion on biological therapy.

[12]  J. Reveille,et al.  The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. , 2013, Arthritis and rheumatism.

[13]  J. Braun,et al.  Withdrawal of biologic therapy in axial spondyloarthritis: the experience in established disease. , 2013, Clinical and experimental rheumatology.

[14]  J. Braun,et al.  Remission and possible discontinuation of biological therapy in axial spondyloarthritis. , 2013, Clinical and experimental rheumatology.

[15]  I. V. D. Horst-Bruinsma Treatment of non-radiographic axial spondyloarthritis: it is only the beginning. , 2013 .

[16]  I. E. van der Horst-Bruinsma Treatment of non-radiographic axial spondyloarthritis: it is only the beginning , 2013, Annals of the rheumatic diseases.

[17]  Jian Wang,et al.  Management of hip involvement in ankylosing spondylitis , 2013, Clinical Rheumatology.

[18]  Л. И. Мясоутова,et al.  Опыт применения ритуксимаба у пациентов с анкилозирующим спондилитом , 2013 .

[19]  J. Listing,et al.  Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial , 2012, Annals of the rheumatic diseases.

[20]  E. Pathan,et al.  Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis , 2012, Annals of the rheumatic diseases.

[21]  A. Loft,et al.  Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry , 2012, Annals of the rheumatic diseases.

[22]  Junmin Chen,et al.  Methotrexate for ankylosing spondylitis. , 2013, The Cochrane database of systematic reviews.

[23]  J. Braun,et al.  Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease. , 2013, Clinical and experimental rheumatology.

[24]  V. Bykerk,et al.  Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials , 2013, Rheumatology International.

[25]  H. Direskeneli,et al.  Conventional DMARD therapy (methotrexate‐sulphasalazine) may decrease the requirement of biologics in routine practice of ankylosing spondylitis patients: A real‐life experience , 2012, International journal of rheumatic diseases.

[26]  A. Deodhar,et al.  The “Knowns” and “Unknowns” of Biologic Therapy in Ankylosing Spondylitis , 2012, The American journal of the medical sciences.

[27]  Шандор Федорович Эрдес Эффективность адалимумаба при увеитах у больных анкилозирующим спондилитом , 2012 .

[28]  G. Burmester,et al.  Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial , 2012, Annals of the rheumatic diseases.

[29]  E. Märker-Hermann,et al.  Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort , 2012, Annals of the rheumatic diseases.

[30]  F. Breedveld,et al.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011 , 2006, Annals of the rheumatic diseases.

[31]  V. Preedy,et al.  Nonsteroidal Anti-inflammatory Drugs , 2010 .

[32]  M. Soubrier,et al.  Mixed effect of tocilizumab in spondylarthritis. Comments about the article by Wendling et al. entitled "Short-term effect of IL-6 inhibition in spondylarthritis". Joint Bone Spine 2010;77:624-5. , 2012, Joint, bone, spine : revue du rhumatisme.

[33]  P. Goupille,et al.  Therapeutic Drug Monitoring of Infliximab in Spondyloarthritis: An Observational Open-Label Study , 2011, Therapeutic drug monitoring.

[34]  Dongxue Wang,et al.  Efficacy of etanercept in ankylosing spondylitis hip lesions. , 2011, Joint, bone, spine : revue du rhumatisme.

[35]  M. Dougados,et al.  2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis , 2011, Annals of the rheumatic diseases.

[36]  J. Braun,et al.  Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study , 2011, Annals of the rheumatic diseases.

[37]  Анна Георгиевна Бочкова Роль глюкокортикоидов в лечении спондилоартритов , 2011 .

[38]  Piet Geusens,et al.  Predicting the outcome of ankylosing spondylitis therapy , 2011, Annals of the rheumatic diseases.

[39]  Andreas Krause,et al.  Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial , 2011, Annals of the rheumatic diseases.

[40]  M. Weisman,et al.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010 , 2011, Annals of the rheumatic diseases.

[41]  Array Ф. Эрдес,et al.  Опыт длительной терапии инфликсимабом у больных анкилозирующим спондилитом , 2010, RSP 2010.

[42]  M. Dougados,et al.  Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis. , 2010, Rheumatology.

[43]  W. Maksymowych,et al.  A Double-blind, Placebo-controlled Trial of Low Dose Infliximab in Ankylosing Spondylitis , 2010, The Journal of Rheumatology.

[44]  I. Olivieri,et al.  Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. , 2010, Rheumatology.

[45]  Шандор Федорович Эрдес,et al.  ПЕРВЫЙ ОПЫТ ПРИМЕНЕНИЯ АДАЛИМУМАБАУ БОЛЬНЫХ АНКИЛОЗИРУЮЩИМ СПОНДИЛИТОМ:КЛИНИЧЕСКОЕ И МРТ-СОПОСТАВЛЕНИЕ РЕЗУЛЬТАТОВ ТЕРАПИИ , 2010, RSP 2010.

[46]  F. Erdes,et al.  Ключевые слова: инфликсимаб, анкилозирующий спондилит, сакроилиит, энтезит, ремиссия EXPERIENCE WITH LONG-TERM INFLIXIMAB THERAPY IN PATIENTS WITH ANKYLOSING SPONDYLITIS , 2010 .

[47]  A. Boonen,et al.  Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. , 2010, Rheumatology.

[48]  D. Allan,et al.  Concomitant cervical and thoracic spinal fractures in ankylosing spondylitis: A case report and review of literature , 2009 .

[49]  G. Sapkas,et al.  Surgical outcome after spinal fractures in patients with ankylosing spondylitis , 2009, BMC musculoskeletal disorders.

[50]  T. Albert,et al.  The Management of Spinal Injuries in Patients With Ankylosing Spondylitis or Diffuse Idiopathic Skeletal Hyperostosis: A Comparison of Treatment Methods and Clinical Outcomes , 2009, Journal of Spinal Disorders & Techniques.

[51]  T. Kiaer,et al.  Transpedicular closed wedge osteotomy in ankylosing spondylitis: results of surgical treatment and prospective outcome analysis , 2009, European Spine Journal.

[52]  F. Oner,et al.  Spinal fractures in patients with ankylosing spinal disorders: a systematic review of the literature on treatment, neurological status and complications , 2009, European Spine Journal.

[53]  J. Sieper,et al.  Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. , 2008, Arthritis and rheumatism.

[54]  В. М. Дурлештер,et al.  Первый опыт применения комбинированной хромоскопии у пациентов с гастроэзофагеальной рефлюксной болезнью , 2008 .

[55]  K. Pavelka [Early diagnosis of ankylosing spondylitis]. , 2006, Vnitrni lekarstvi.

[56]  S. van der Linden,et al.  Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy. , 2006, Best practice & research. Clinical rheumatology.

[57]  M. Dougados,et al.  Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. , 2005, Arthritis and rheumatism.

[58]  M. Dougados,et al.  International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis , 2003, Annals of the rheumatic diseases.

[59]  M. Rudawaleit [Early diagnosis of ankylosing spondylitis]. , 2003, Zeitschrift fur Rheumatologie.

[60]  E. Veys,et al.  Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up , 2002, Annals of the rheumatic diseases.

[61]  P. Emery,et al.  Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. , 2001, Arthritis and rheumatism.

[62]  Яков Александрович Сигидин,et al.  Контролируемая оценка эффективности сульфасалазина при анкилозирующем спондилоартрите , 2001 .

[63]  H. Dagfinrud,et al.  Physiotherapy interventions for ankylosing spondylitis. , 2001, The Cochrane database of systematic reviews.

[64]  D. Baeten,et al.  Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study , 2000, Annals of the rheumatic diseases.

[65]  D. Mosher,et al.  Efficacy of sacroiliac corticosteroid injections in patients with inflammatory spondyloarthropathy: results of a 6 month controlled study. , 2000, The Journal of rheumatology.

[66]  A. Sicard [Spinal fractures]. , 1974, Journal de chirurgie.